Stathmin is a marker of progression and poor prognosis in esophageal carcinoma

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 8, 2014, Pages 3613-3618

  Wang, Feng ^a   Xuan, Xiao Yan ^b   Yang, Xuan ^b   Cao, Lei ^a   Pang, Li Na ^a   Zhou, Ran ^a   Fan, Qin Xia ^a   Wang, Liu Xing ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

Biomarker; Esophageal carcinoma; Stathmin

Indexed keywords

MESSENGER RNA; STATHMIN; STMN1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; CANCER STAGING; CARCINOMA; DISEASE COURSE; ESOPHAGUS TUMOR; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ADULT; AGED; CARCINOMA; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RNA, MESSENGER; STATHMIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84901981450     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.8.3613     Document Type: Article

References (25)

1. D'Andrea S, Berton S, Segatto I, et al (2012). Stathmin is dispensable for tumor onset in mice. PLoS One, 7, 45561.
2. Han ZX, Wang HM, Jiang G, et al (2013). Overcoming paclitaxel resistance in lung cancer cells via dual inhibition of stathmin and Bcl-2. Cancer Biother Radiopharm, 28, 398-405.
3. He W, Li K, Wang F, Qin YR, Fan QX (2012). Expression of OCT4 in human esophageal squamous cell carcinoma is significantly associated with poorer prognosis. World J Gastroenterol, 18, 712-9.
4. Holmfeldt P, Larsson N, Segerman B, et al (2001). The Catastrophe-promoting Activity of Ectopic Op18/Stathmin Is Required for Disruption of Mitotic Spindles But Not Interphase Microtubules. Mol Biol Cell, 12, 73-83.
5. Hou X, Wei JC, Wu JX et al (2013). Multidisciplinary modalities achieve encouraging long-term survival in resectable limited-disease esophageal small cell carcinoma. PLoS One, 8, 69259.
6. Iancu-Rubin C, Gajzer D, Tripodi J, et al (2011). Down-regulation of stathmin expression is required for megakaryocyte maturation and platelet production. Blood, 117, 4580-9.
7. Jeon TY, Han ME, Lee YW, et al (2010). Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells. Br J Cancer, 102, 710-18.
8. Karst AM, Levanon K, Duraisamy S, et al (2011). Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. Gynecol Oncol, 123, 5-12.
9. Kouzu Y, Uzawa K, Koike H, et al (2006). Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis. Br J Cancer, 94, 717-23.
10. Li N, Jiang P, Du W, et al (2011). Siva1 suppresses epithelial-mesenchymal transition and metastasis of tumor cells by inhibiting stathmin and stabilizing microtubules. Proc Natl Acad Sci USA, 108, 12851-6.
11. Liu F, Sun YL, Xu Y, et al (2013). Expression and phosphorylation of stathmin correlate with cell migration in esophageal squamous cell carcinoma. Oncol Rep, 29, 419-24.
12. Miceli C, Tejada A, Castaneda A, Mistry SJ (2013). Cell cycle inhibition therapy that targets stathmin in in vitro and in vivo models of breast cancer. Cancer Gene Ther, 20, 298-307.
13. Qi B, Yao WJ, Zhao BS, et al (2013), Involvement of microRNA-198 overexpression in the poor prognosis of esophageal cancer. Asian Pac J Cancer Prev, 14, 5073-6.
14. Song PI, Liang H, Fan JH, et al (2011). Long-term survival after esophagectomy for early esophageal squamous cell carcinoma in Linxian, China. J Surg Oncol, 104, 176-80.
15. Tian X, Tian Y, Sarich N, Wu T, Birukova AA (2013). Novel role of stathmin in microtubule-dependent control of endothelial permeability. FASEB J, 26, 3862-74.
16. Tsvetkov PO, Barbier P, Breuzard G, Peyrot V, Devred F (2013). Microtubule- associated proteins and tubulin interaction by isothermal titration calorimetry. Methods Cell Biol, 115, 283-302.
17. Wang Q, Ma C, Kemmner W (2013). Wdr66 is a novel marker for risk stratification and involved in epithelial-mesenchymal transition of esophageal squamous cellcarcinoma. BMC Cancer, 13, 137.
18. Wang R, Dong K, Lin F, et al (2007). Inhibiting proliferation and enhancing chemosensitivity to taxanes in osteosarcoma cells by RNA interference-mediated downregulation of stathmin expression. Mol Med, 13, 567-75.
19. Werner HM, Trovik J, Halle MK, et al (2014). Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer. PLoS One, 9, 90141.
20. Wosnitzer MS, Domingo-Domenech J, Castillo-Martin M, et al (2011). Predictive value of microtubule associated proteins tau and stathmin in patients with nonmuscle invasive bladder cancer receiving adjuvant intravesical taxane therapy. J Urol, 186, 2094-100.
21. Wu IC, Wu CC, Lu CY, et al (2013). Substance use (Alcohol, Areca Nut and Cigarette) is associated with poor prognosis of esophageal squamous cell carcinoma. PLoS One, 8, 55834.
22. Ying L, Su D, Zhu J, et al (2013). Genotyping of stathmin and its association with clinical factors and survival in patients with ovariancancer. Oncol Lett, 5, 1315-20.
23. Yoon MS, Nam TK, Lee JS, et al (2011). VEGF as a predictor for response to definitive chemoradiotherapy and COX-2 as a prognosticator for survival in esophageal squamous cell carcinoma. Korean Med Sci, 26, 513-20.
24. Yuan SF, Chen WJ, Zhu LJ, et al (2013). Effects of monoclonal antibodies against human stathmin combined with paclitaxel on proliferation of the QG-56human lung carcinoma cell line. Asian Pac J Cancer Prev, 13, 2967-71.
25. Yuen HF, McCrudden CM, Chan KK, et al (2011). The Role of pea3 group transcription factors in esophageal squamous cell carcinoma. Am J Pathol, 179, 992-1003.